{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:08:58Z","timestamp":1791486538450,"version":"4.3.4"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11904-023-00669-7","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T07:02:11Z","timestamp":1698303731000},"page":"405-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fatty Liver Disease: Enter the Metabolic Era"],"prefix":"10.1007","volume":"20","author":[{"given":"Kara","family":"Wegermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Moylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Naggie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"5","key":"669_CR1","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"key":"669_CR2","unstructured":"Rinella ME et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023 [online ahead of print]."},{"issue":"17","key":"669_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559\u201369.","journal-title":"N Engl J Med"},{"issue":"1","key":"669_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"669_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97 e10.","journal-title":"Gastroenterology"},{"issue":"12","key":"669_CR6","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1097\/QAD.0000000000003312","volume":"36","author":"M Michel","year":"2022","unstructured":"Michel M, et al. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV. AIDS. 2022;36(12):1665\u201374.","journal-title":"AIDS"},{"issue":"11","key":"669_CR7","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","volume":"31","author":"JB Maurice","year":"2017","unstructured":"Maurice JB, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS. 2017;31(11):1621\u201332.","journal-title":"AIDS"},{"issue":"12","key":"669_CR8","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.dld.2016.08.117","volume":"48","author":"R Lombardi","year":"2016","unstructured":"Lombardi R, et al. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Dig Liver Dis. 2016;48(12):1471\u20137.","journal-title":"Dig Liver Dis"},{"issue":"17","key":"669_CR9","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1097\/QAD.0000000000001241","volume":"30","author":"\u00c9 Vuille-Lessard","year":"2016","unstructured":"Vuille-Lessard \u00c9, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS. 2016;30(17):2635\u201343.","journal-title":"AIDS"},{"issue":"5","key":"669_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/QAI.0b013e318198a88a","volume":"50","author":"N Crum-Cianflone","year":"2009","unstructured":"Crum-Cianflone N, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464\u201373.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"669_CR11","doi-asserted-by":"publisher","first-page":"e571","DOI":"10.1093\/cid\/ciac708","volume":"76","author":"KW Chew","year":"2023","unstructured":"Chew KW, et al. Liver Inflammation Is Common and Linked to Metabolic Derangements in Persons With Treated Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2023;76(3):e571\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"669_CR12","doi-asserted-by":"publisher","first-page":"ofac538","DOI":"10.1093\/ofid\/ofac538","volume":"9","author":"C Riebensahm","year":"2022","unstructured":"Riebensahm C, et al. Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy. Open Forum Infect Dis. 2022;9(11):ofac538.","journal-title":"Open Forum Infect Dis"},{"key":"669_CR13","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Gawrieh S, et al. Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study. Hepatology 2023;78(2):578\u2013591. Large multi-center study in the US providing prevalence estimate of MASLD based on transient elastography.","DOI":"10.1097\/HEP.0000000000000313"},{"issue":"4","key":"669_CR14","doi-asserted-by":"publisher","first-page":"e055706","DOI":"10.1136\/bmjopen-2021-055706","volume":"12","author":"J Price","year":"2022","unstructured":"Price J, et al. Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. BMJ Open. 2022;12(4):e055706.","journal-title":"BMJ Open"},{"key":"669_CR15","doi-asserted-by":"crossref","unstructured":"\u2022\u00a0Kalligeros M, et al. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2023;21(7):1708\u20131722.\u00a0Recent systematic review and meta-analysis of prevalence and risk factors for MASLD in PWH.","DOI":"10.1016\/j.cgh.2023.01.001"},{"issue":"3","key":"669_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cgh.2022.03.048","volume":"21","author":"M Lemoine","year":"2023","unstructured":"\u2022 Lemoine M, et al. Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2023;21(3):713-722.e3. Lays out a potential screening strategy for MASLD in PWH based on risk factors and non-invasive testing.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"669_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"8","key":"669_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u201352.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"669_CR19","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1093\/cid\/ciaa430","volume":"71","author":"A Cervo","year":"2020","unstructured":"Cervo A, et al. Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus. Clin Infect Dis. 2020;71(10):e694\u2013701.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"669_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/ajg.2014.32","volume":"109","author":"JC Price","year":"2014","unstructured":"Price JC, et al. Risk factors for fatty liver in the Multicenter AIDS Cohort Study. Am J Gastroenterol. 2014;109(5):695\u2013704.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"669_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/QAI.0b013e318074efe3","volume":"45","author":"SS Mohammed","year":"2007","unstructured":"Mohammed SS, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr. 2007;45(4):432\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"669_CR22","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.30914","volume":"71","author":"T Barr\u00e9","year":"2020","unstructured":"Barr\u00e9 T, et al. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology. 2020;71(4):1182\u201397.","journal-title":"Hepatology"},{"issue":"9","key":"669_CR23","doi-asserted-by":"publisher","first-page":"e3275","DOI":"10.1093\/cid\/ciaa1303","volume":"73","author":"M Khalili","year":"2021","unstructured":"Khalili M, et al. Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clin Infect Dis. 2021;73(9):e3275\u201385.","journal-title":"Clin Infect Dis"},{"key":"669_CR24","doi-asserted-by":"publisher","first-page":"893579","DOI":"10.3389\/fped.2022.893579","volume":"10","author":"PC Rose","year":"2022","unstructured":"Rose PC, et al. Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. Front Pediatr. 2022;10:893579.","journal-title":"Front Pediatr"},{"issue":"6","key":"669_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/QAD.0000000000003170","volume":"36","author":"I Carrasco","year":"2022","unstructured":"Carrasco I, et al. Prevalence of nonalcoholic fatty liver disease using noninvasive techniques among children, adolescents, and youths living with HIV. AIDS. 2022;36(6):805\u201314.","journal-title":"AIDS"},{"issue":"2","key":"669_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/infdis\/jiz096","volume":"220","author":"JA Aepfelbacher","year":"2019","unstructured":"Aepfelbacher JA, et al. Increased Prevalence of Hepatic Steatosis in Young Adults With Lifelong HIV. J Infect Dis. 2019;220(2):266\u20139.","journal-title":"J Infect Dis"},{"issue":"4","key":"669_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/apt.13052","volume":"41","author":"I Vodkin","year":"2015","unstructured":"Vodkin I, et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41(4):368\u201378.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"669_CR28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/cid\/ciaa382","volume":"72","author":"LT Fourman","year":"2021","unstructured":"Fourman LT, et al. Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;72(12):2087\u201394.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"669_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jhep.2017.05.011","volume":"67","author":"T Pembroke","year":"2017","unstructured":"Pembroke T, et al. Hepatic steatosis progresses faster in HIV mono-infected than HIV\/HCV co-infected patients and is associated with liver fibrosis. J Hepatol. 2017;67(4):801\u20138.","journal-title":"J Hepatol"},{"issue":"1","key":"669_CR30","doi-asserted-by":"publisher","first-page":"ofz509","DOI":"10.1093\/ofid\/ofz509","volume":"7","author":"JM Paik","year":"2020","unstructured":"Paik JM, et al. Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006-2016. Open Forum Infect Dis. 2020;7(1):ofz509.","journal-title":"Open Forum Infect Dis"},{"key":"669_CR31","doi-asserted-by":"crossref","unstructured":"Han WM, et al. Non-alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis with liver fibrosis as predictors of new onset Diabetes Mellitus in People living with HIV: A Longitudinal Cohort Study. Clin Infect Dis 2023:ciad433 [online ahead of print].","DOI":"10.1093\/cid\/ciad433"},{"issue":"5","key":"669_CR32","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/infdis\/jiaa170","volume":"222","author":"T Krahn","year":"2020","unstructured":"Krahn T, et al. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection. J Infect Dis. 2020;222(5):787\u201397.","journal-title":"J Infect Dis"},{"issue":"12","key":"669_CR33","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/cid\/ciu701","volume":"59","author":"J Schouten","year":"2014","unstructured":"Schouten J, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014;59(12):1787\u201397.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"669_CR34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/hiv.13274","volume":"23","author":"A Cervo","year":"2022","unstructured":"Cervo A, et al. Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV. HIV Med. 2022;23(8):911\u201321.","journal-title":"HIV Med"},{"issue":"11","key":"669_CR35","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1093\/cid\/ciab552","volume":"73","author":"PS Douglas","year":"2021","unstructured":"Douglas PS, et al. Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021;73(11):2009\u201322.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"669_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/QAI.0000000000002359","volume":"84","author":"A Kaplan","year":"2020","unstructured":"Kaplan A, et al. Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV. J Acquir Immune Defic Syndr. 2020;84(4):400\u20134.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"669_CR37","doi-asserted-by":"crossref","unstructured":"Krishnan A, et al. Risk of Adverse cardiovascular outcomes among persons living with HIV and nonalcoholic fatty liver disease: a multicenter matched cohort study. Aids 2023 Mar 6 [online ahead of print].","DOI":"10.1097\/QAD.0000000000003537"},{"issue":"3","key":"669_CR38","first-page":"E219","volume":"58","author":"A Zizza","year":"2017","unstructured":"Zizza A, et al. Atherosclerosis is associated with a higher risk of hepatic steatosis in HIV-infected patients. J Prev Med Hyg. 2017;58(3):E219-e224.","journal-title":"J Prev Med Hyg"},{"issue":"8","key":"669_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1468-1293.2010.00904.x","volume":"12","author":"N Crum-Cianflone","year":"2011","unstructured":"Crum-Cianflone N, et al. Fatty liver disease is associated with underlying cardiovascular disease in HIV-infected persons(*). HIV Med. 2011;12(8):463\u201371.","journal-title":"HIV Med"},{"key":"669_CR40","unstructured":"\u2022\u00a0Grinspoon SK, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med 2023;389(8):687\u2013699.\u00a0Very recent randomized trial of statin vs placebo in PWH with ASCVD risk of less than 15%. Pitavastatin resulted in a significant reduction in major adverse cardiovascular events. The trial was stopped early due to this effect."},{"issue":"13","key":"669_CR41","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1097\/QAD.0000000000002650","volume":"34","author":"J Milic","year":"2020","unstructured":"Milic J, et al. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV. AIDS. 2020;34(13):1915\u201321.","journal-title":"AIDS"},{"issue":"3","key":"669_CR42","first-page":"150","volume":"8","author":"P Debroy","year":"2019","unstructured":"Debroy P, et al. Relationship between Grip Strength and Nonalcoholic Fatty Liver Disease in Men Living with HIV Referred to a Metabolic Clinic. J Frailty Aging. 2019;8(3):150\u20133.","journal-title":"J Frailty Aging"},{"issue":"2","key":"669_CR43","doi-asserted-by":"publisher","first-page":"e0279685","DOI":"10.1371\/journal.pone.0279685","volume":"18","author":"S Gawrieh","year":"2023","unstructured":"Gawrieh S, et al. Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virus. PLoS One. 2023;18(2):e0279685.","journal-title":"PLoS One"},{"issue":"8","key":"669_CR44","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/hep4.1958","volume":"6","author":"M Michel","year":"2022","unstructured":"Michel M, et al. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatol Commun. 2022;6(8):2011\u201321.","journal-title":"Hepatol Commun"},{"issue":"3","key":"669_CR45","doi-asserted-by":"publisher","first-page":"e0150970","DOI":"10.1371\/journal.pone.0150970","volume":"11","author":"KA Nguyen","year":"2016","unstructured":"Nguyen KA, et al. A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population. PLoS One. 2016;11(3):e0150970.","journal-title":"PLoS One"},{"issue":"7","key":"669_CR46","doi-asserted-by":"publisher","first-page":"e2184","DOI":"10.1093\/cid\/ciaa1302","volume":"73","author":"JB Maurice","year":"2021","unstructured":"Maurice JB, et al. Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. Clin Infect Dis. 2021;73(7):e2184\u201393.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"669_CR47","doi-asserted-by":"publisher","first-page":"e0168265","DOI":"10.1371\/journal.pone.0168265","volume":"11","author":"R N\u00fa\u00f1ez-Torres","year":"2016","unstructured":"N\u00fa\u00f1ez-Torres R, et al. The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV\/Hepatitis C Virus Coinfected Patients. PLoS One. 2016;11(12):e0168265.","journal-title":"PLoS One"},{"key":"669_CR48","doi-asserted-by":"publisher","first-page":"905126","DOI":"10.3389\/fphar.2022.905126","volume":"13","author":"C Busca","year":"2022","unstructured":"Busca C, et al. Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD. Front Pharmacol. 2022;13:905126.","journal-title":"Front Pharmacol"},{"issue":"8","key":"669_CR49","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/hiv.12489","volume":"18","author":"R N\u00fa\u00f1ez-Torres","year":"2017","unstructured":"N\u00fa\u00f1ez-Torres R, et al. Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. HIV Med. 2017;18(8):546\u201354.","journal-title":"HIV Med"},{"issue":"15","key":"669_CR50","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1097\/QAD.0000000000000799","volume":"29","author":"J Macias","year":"2015","unstructured":"Macias J, et al. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. AIDS. 2015;29(15):1927\u201335.","journal-title":"AIDS"},{"issue":"1","key":"669_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/v14010122","volume":"14","author":"M Sapula","year":"2022","unstructured":"Sapula M, et al. Impact of combined antiretroviral therapy on metabolic syndrome components in adult people living with HIV: A literature review. Viruses. 2022;14(1):122.","journal-title":"Viruses"},{"issue":"7","key":"669_CR52","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/hep4.1695","volume":"5","author":"CL Gabriel","year":"2021","unstructured":"Gabriel CL, et al. Hepatic Steatosis and Ectopic Fat Are Associated With Differences in Subcutaneous Adipose Tissue Gene Expression in People With HIV. Hepatol Commun. 2021;5(7):1224\u201337.","journal-title":"Hepatol Commun"},{"issue":"12","key":"669_CR53","doi-asserted-by":"publisher","first-page":"ofz468","DOI":"10.1093\/ofid\/ofz468","volume":"6","author":"JC Price","year":"2019","unstructured":"Price JC, et al. Sex Hormone-Binding Globulin Levels Are Inversely Associated With Nonalcoholic Fatty Liver Disease in HIV-Infected and -Uninfected Men. Open Forum Infect Dis. 2019;6(12):ofz468.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"669_CR54","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/QAD.0000000000002133","volume":"33","author":"JB Maurice","year":"2019","unstructured":"Maurice JB, et al. Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. AIDS. 2019;33(5):805\u201314.","journal-title":"AIDS"},{"issue":"4","key":"669_CR55","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40121-022-00654-4","volume":"11","author":"P Villoslada-Blanco","year":"2022","unstructured":"Villoslada-Blanco P, et al. Integrase Inhibitors Partially Restore Bacterial Translocation, Inflammation and Gut Permeability Induced by HIV Infection: Impact on Gut Microbiota. Infect Dis Ther. 2022;11(4):1541\u201357.","journal-title":"Infect Dis Ther"},{"issue":"7","key":"669_CR56","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1053\/j.gastro.2022.01.058","volume":"162","author":"KC Bauer","year":"2022","unstructured":"Bauer KC, et al. Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective. Gastroenterology. 2022;162(7):1858-1875 e2.","journal-title":"Gastroenterology"},{"issue":"7","key":"669_CR57","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1007\/s10620-023-07860-1","volume":"68","author":"CL Hsu","year":"2023","unstructured":"Hsu CL, et al. Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease. Dig Dis Sci. 2023;68(7):3059\u201369.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"669_CR58","first-page":"328","volume":"4","author":"JD Debes","year":"2016","unstructured":"Debes JD, Bohjanen PR, Boonstra A. Mechanisms of Accelerated Liver Fibrosis Progression during HIV Infection. J Clin Transl Hepatol. 2016;4(4):328\u201335.","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"669_CR59","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1089\/aid.2017.0314","volume":"34","author":"SS Bailin","year":"2018","unstructured":"Bailin SS, et al. Lower Concentrations of Circulating Medium and Long-Chain Acylcarnitines Characterize Insulin Resistance in Persons with HIV. AIDS Res Hum Retroviruses. 2018;34(6):536\u201343.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"669_CR60","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"key":"669_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2334-13-203","volume":"13","author":"E Cassol","year":"2013","unstructured":"Cassol E, et al. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis. 2013;13:203.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"669_CR62","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/cells10010174","volume":"10","author":"M Schank","year":"2021","unstructured":"Schank M, et al. The impact of HIV- and ART-Induced mitochondrial dysfunction in cellular senescence and aging. Cells. 2021;10(1):174.","journal-title":"Cells"},{"issue":"5","key":"669_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/aid.2020.0177","volume":"37","author":"JH Sim","year":"2021","unstructured":"Sim JH, et al. Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection. AIDS Res Hum Retroviruses. 2021;37(5):385\u201390.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"669_CR64","doi-asserted-by":"crossref","unstructured":"Fourman LT, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020;5(16):e140134.","DOI":"10.1172\/jci.insight.140134"},{"issue":"4","key":"669_CR65","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/infdis\/jiac475","volume":"227","author":"LT Fourman","year":"2023","unstructured":"Fourman LT, et al. Proteomic Analysis of Hepatic Fibrosis in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease Demonstrates Up-regulation of Immune Response and Tissue Repair Pathways. J Infect Dis. 2023;227(4):565\u201376.","journal-title":"J Infect Dis"},{"key":"669_CR66","doi-asserted-by":"publisher","first-page":"1099356","DOI":"10.3389\/fimmu.2023.1099356","volume":"14","author":"CN Wanjalla","year":"2023","unstructured":"Wanjalla CN, et al. CD4(+) T cells expressing CX3CR1, GPR56, with variable CD57 are associated with cardiometabolic diseases in persons with HIV. Front Immunol. 2023;14:1099356.","journal-title":"Front Immunol"},{"issue":"16","key":"669_CR67","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.7150\/thno.27428","volume":"8","author":"A Pera","year":"2018","unstructured":"Pera A, et al. CD28(null) pro-atherogenic CD4 T-cells explain the link between CMV infection and an increased risk of cardiovascular death. Theranostics. 2018;8(16):4509\u201319.","journal-title":"Theranostics"},{"key":"669_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2017.00195","volume":"8","author":"I Broadley","year":"2017","unstructured":"Broadley I, et al. Expansions of Cytotoxic CD4(+)CD28(-) T Cells Drive Excess Cardiovascular Mortality in Rheumatoid Arthritis and Other Chronic Inflammatory Conditions and Are Triggered by CMV Infection. Front Immunol. 2017;8:195.","journal-title":"Front Immunol"},{"key":"669_CR69","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.eclinm.2021.101116","volume":"40","author":"J Bischoff","year":"2021","unstructured":"Bischoff J, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART). EClinicalMedicine. 2021;40:101116.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"669_CR70","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/jcm9051246","volume":"9","author":"A Curran","year":"2020","unstructured":"Curran A, et al. Lipidomics reveals reduced inflammatory lipid species and storage lipids after switching from EFV\/FTC\/TDF to RPV\/FTC\/TDF: A randomized open-label trial. J Clin Med. 2020;9(5):1246.","journal-title":"J Clin Med"},{"issue":"4","key":"669_CR71","doi-asserted-by":"publisher","first-page":"e25484","DOI":"10.1002\/jia2.25484","volume":"23","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, et al. Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020;23(4):e25484.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"669_CR72","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1093\/infdis\/jiaa246","volume":"222","author":"DM Kirkegaard-Klitbo","year":"2020","unstructured":"Kirkegaard-Klitbo DM, et al. Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. J Infect Dis. 2020;222(8):1353\u201362.","journal-title":"J Infect Dis"},{"issue":"3","key":"669_CR73","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1093\/cid\/ciab057","volume":"73","author":"DM Kirkegaard-Klitbo","year":"2021","unstructured":"Kirkegaard-Klitbo DM, et al. Hepatic Steatosis Associated With Exposure to Elvitegravir and Raltegravir. Clin Infect Dis. 2021;73(3):e811\u20134.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"669_CR74","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/cid\/cix467","volume":"65","author":"J Mac\u00edas","year":"2017","unstructured":"Mac\u00edas J, et al. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2017;65(6):1012\u20139.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"669_CR75","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/23744235.2019.1629008","volume":"51","author":"L Calza","year":"2019","unstructured":"Calza L, et al. Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. Infect Dis (Lond). 2019;51(8):593\u2013601.","journal-title":"Infect Dis (Lond)"},{"issue":"4","key":"669_CR76","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s11904-009-0030-z","volume":"6","author":"A Anema","year":"2009","unstructured":"Anema A, et al. Food insecurity and HIV\/AIDS: current knowledge, gaps, and research priorities. Curr HIV\/AIDS Rep. 2009;6(4):224\u201331.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"669_CR77","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/09540121.2010.498908","volume":"23","author":"A Anema","year":"2011","unstructured":"Anema A, et al. High prevalence of food insecurity among HIV-infected individuals receiving HAART in a resource-rich setting. AIDS Care. 2011;23(2):221\u201330.","journal-title":"AIDS Care"},{"issue":"3","key":"669_CR78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/ajcn\/nqaa362","volume":"113","author":"JA Tamargo","year":"2021","unstructured":"Tamargo JA, et al. Food insecurity is associated with magnetic resonance-determined nonalcoholic fatty liver and liver fibrosis in low-income, middle-aged adults with and without HIV. Am J Clin Nutr. 2021;113(3):593\u2013601.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"669_CR79","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1080\/03670244.2021.1875453","volume":"60","author":"H Tutunchi","year":"2021","unstructured":"Tutunchi H, et al. Food Insecurity and Lipid Profile Abnormalities Are Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease (NAFLD): A Case-Control Study. Ecol Food Nutr. 2021;60(4):508\u201324.","journal-title":"Ecol Food Nutr"},{"issue":"7","key":"669_CR80","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/MCG.0000000000001741","volume":"57","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Mehta M, Leung CW. Food Insecurity Is Associated With Chronic Liver Disease Among US Adults. J Clin Gastroenterol. 2023;57(7):737\u201342.","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"669_CR81","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1097\/HEP.0000000000000465","volume":"78","author":"G Sebastiani","year":"2023","unstructured":"Sebastiani G, et al. Letter to the editor: People living with HIV and NAFLD: A population left behind in the global effort for liver fibrosis screening? Hepatology. 2023;78(5):E87\u20138.","journal-title":"Hepatology"},{"key":"669_CR82","unstructured":"European AIDS Clinical Society. Guidelines: Version 11.0, October 2021. Accessed via https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf.\u00a0"},{"issue":"6","key":"669_CR83","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/hiv.13060","volume":"22","author":"C Yanavich","year":"2021","unstructured":"Yanavich C, et al. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and\/or advanced liver fibrosis in people living with HIV. HIV Med. 2021;22(6):445\u201356.","journal-title":"HIV Med"},{"issue":"7","key":"669_CR84","doi-asserted-by":"publisher","first-page":"ofac279","DOI":"10.1093\/ofid\/ofac279","volume":"9","author":"C Busca","year":"2022","unstructured":"Busca C, et al. Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens. Open Forum Infect Dis. 2022;9(7):ofac279.","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"669_CR85","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.cgh.2014.06.027","volume":"13","author":"MS Siddiqui","year":"2015","unstructured":"Siddiqui MS, et al. Validation of noninvasive methods for detecting hepatic steatosis in patients with human immunodeficiency virus infection. Clin Gastroenterol Hepatol. 2015;13(2):402\u20135.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"669_CR86","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/cid\/ciaa429","volume":"72","author":"VH Ajmera","year":"2021","unstructured":"Ajmera VH, et al. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. Clin Infect Dis. 2021;72(12):2124\u201331.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"669_CR87","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/liv.14107","volume":"39","author":"M Praktiknjo","year":"2019","unstructured":"Praktiknjo M, et al. Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. Liver Int. 2019;39(8):1514\u201320.","journal-title":"Liver Int"},{"issue":"4","key":"669_CR88","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/hep.23050","volume":"50","author":"AE Feldstein","year":"2009","unstructured":"Feldstein AE, et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009;50(4):1072\u20138.","journal-title":"Hepatology"},{"issue":"1","key":"669_CR89","doi-asserted-by":"publisher","first-page":"e0191985","DOI":"10.1371\/journal.pone.0191985","volume":"13","author":"A Benmassaoud","year":"2018","unstructured":"Benmassaoud A, et al. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. PLoS One. 2018;13(1):e0191985.","journal-title":"PLoS One"},{"issue":"12","key":"669_CR90","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/cid\/ciac337","volume":"75","author":"JC Price","year":"2022","unstructured":"Price JC, et al. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score. Clin Infect Dis. 2022;75(12):2119\u201327.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"669_CR91","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S2352-3018(22)00069-8","volume":"9","author":"G Sebastiani","year":"2022","unstructured":"Sebastiani G, et al. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. Lancet HIV. 2022;9(Suppl 1):S4.","journal-title":"Lancet HIV"},{"issue":"4","key":"669_CR92","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1097\/QAI.0000000000001936","volume":"80","author":"M Lemoine","year":"2019","unstructured":"Lemoine M, et al. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. J Acquir Immune Defic Syndr. 2019;80(4):e86\u201394.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"669_CR93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/hiv.12799","volume":"21","author":"G Sebastiani","year":"2020","unstructured":"Sebastiani G, et al. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. HIV Med. 2020;21(2):96\u2013108.","journal-title":"HIV Med"},{"issue":"5","key":"669_CR94","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/liv.13734","volume":"38","author":"CS Chaudhury","year":"2018","unstructured":"Chaudhury CS, et al. Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease. Liver Int. 2018;38(5):797\u2013802.","journal-title":"Liver Int"},{"issue":"5","key":"669_CR95","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/hep.30674","volume":"70","author":"VH Ajmera","year":"2019","unstructured":"Ajmera VH, et al. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial). Hepatology. 2019;70(5):1531\u201345.","journal-title":"Hepatology"},{"issue":"2","key":"669_CR96","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/QAD.0000000000002412","volume":"34","author":"G Sebastiani","year":"2020","unstructured":"Sebastiani G, et al. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. AIDS. 2020;34(2):237\u201344.","journal-title":"AIDS"},{"issue":"12","key":"669_CR97","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","volume":"6","author":"TL Stanley","year":"2019","unstructured":"Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821\u201330.","journal-title":"Lancet HIV"},{"issue":"4","key":"669_CR98","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/ciab019","volume":"73","author":"TL Stanley","year":"2021","unstructured":"Stanley TL, et al. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021;73(4):621\u201330.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"669_CR99","doi-asserted-by":"publisher","first-page":"e0288598","DOI":"10.1371\/journal.pone.0288598","volume":"18","author":"D Bradshaw","year":"2023","unstructured":"Bradshaw D, et al. Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. PLoS One. 2023;18(7):e0288598.","journal-title":"PLoS One"},{"issue":"7","key":"669_CR100","doi-asserted-by":"publisher","first-page":"e035596","DOI":"10.1136\/bmjopen-2019-035596","volume":"10","author":"D Bradshaw","year":"2020","unstructured":"Bradshaw D, et al. Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone. BMJ Open. 2020;10(7):e035596.","journal-title":"BMJ Open"},{"key":"669_CR101","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.clnesp.2021.03.031","volume":"43","author":"S Policarpo","year":"2021","unstructured":"Policarpo S, Machado MV, Cortez-Pinto H. Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial. Clin Nutr ESPEN. 2021;43:329\u201334.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"669_CR102","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13256-019-2078-8","volume":"13","author":"W Yang","year":"2019","unstructured":"Yang W, et al. Bariatric surgery in individuals with human immunodeficiency virus and type 2 diabetes: a case series. J Med Case Rep. 2019;13(1):146.","journal-title":"J Med Case Rep"},{"issue":"5","key":"669_CR103","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/hep.25813","volume":"56","author":"MP Carrieri","year":"2012","unstructured":"Carrieri MP, et al. Elevated coffee consumption and reduced risk of insulin resistance in HIV-HCV coinfected patients (HEPAVIH ANRS CO-13). Hepatology. 2012;56(5):2010.","journal-title":"Hepatology"},{"issue":"4","key":"669_CR104","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jhep.2017.10.025","volume":"68","author":"MP Carrieri","year":"2018","unstructured":"Carrieri MP, et al. The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. J Hepatol. 2018;68(4):845\u20137.","journal-title":"J Hepatol"},{"issue":"6","key":"669_CR105","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.jhep.2017.08.005","volume":"67","author":"MP Carrieri","year":"2017","unstructured":"Carrieri MP, et al. Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. J Hepatol. 2017;67(6):1157\u201367.","journal-title":"J Hepatol"},{"issue":"12","key":"669_CR106","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1093\/cid\/cix716","volume":"65","author":"EM Kelly","year":"2017","unstructured":"Kelly EM, et al. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus\/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study. Clin Infect Dis. 2017;65(12):2050\u20136.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"669_CR107","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen T, et al. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. J Hepatol. 2018;68(5):1063\u201375.","journal-title":"J Hepatol"},{"issue":"2","key":"669_CR108","doi-asserted-by":"publisher","first-page":"e13808","DOI":"10.1111\/tid.13808","volume":"24","author":"S Shimada","year":"2022","unstructured":"Shimada S, et al. Improvements in liver transplant outcomes in patients with HCV\/HIV coinfection after the introduction of direct-acting antiviral therapies. Transpl Infect Dis. 2022;24(2):e13808.","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"669_CR109","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/ajt.16886","volume":"22","author":"CM Durand","year":"2022","unstructured":"Durand CM, et al. HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV. Am J Transplant. 2022;22(3):853\u201364.","journal-title":"Am J Transplant"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-023-00669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-023-00669-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-023-00669-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T10:12:55Z","timestamp":1702462375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-023-00669-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s11904-023-00669-7","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"20 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}